This Event is licensed under the Creative Commons BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Event: 2023
Key Event Title
Inhibition of Ceramide Synthase
Short name
Biological Context
Level of Biological Organization |
---|
Molecular |
Cell term
Organ term
Key Event Components
Key Event Overview
AOPs Including This Key Event
AOP Name | Role of event in AOP | Point of Contact | Author Status | OECD Status |
---|---|---|---|---|
CerS leads to NTDs | MolecularInitiatingEvent | Lola Bajard (send email) | Open for citation & comment |
Taxonomic Applicability
Life Stages
Sex Applicability
Key Event Description
Ceramide synthases (CerS) are enzymes that catalyze the acylation of Sphiganine (Sa) to form (dihydro-)ceramide (a precursor for ceramide and complex sphingolipds) and also the reacylation of Sphingosine (So) that is derived from the turnover of complex sphingolipids (EFSA et al., 2018; Sassa et al., 2016). Six mammalian isoforms of ceramide synthases exist (CerS1–6), which differ in their tissue distribution as well as in their specificity of the fatty acid chain length used for N-acylation (EFSA et al., 2018; Stiban et al., 2010; Tidhar and Futerman, 2013). The inhibition of CerS results in an increase of Sa, So, and, often, Sa/So ratio. Among others, two possible effects of CerS inhibition are 1) a decrease in the level of ceramides and complex sphingolipids (Riley and Merrill, 2019) and 2) an increase in the phosphorylated forms of Sa and So (Gelineau-van Waes et al., 2012).
How It Is Measured or Detected
Domain of Applicability
References
EFSA, Knutsen, H.K., Barregård, L., Bignami, M., Brüschweiler, B., Ceccatelli, S., Cottrill, B., Dinovi, M., Edler, L., Grasl-Kraupp, B., Hogstrand, C., Hoogenboom, L. (Ron), Nebbia, C.S., Petersen, A., Rose, M., Roudot, A.C., Schwerdtle, T., Vleminckx, C., Vollmer, G., Wallace, H., Dall’Asta, C., Gutleb, A.C., Humpf, H.U., Galli, C., Metzler, M., Oswald, I.P., Parent-Massin, D., Binaglia, M., Steinkellner, H., Alexander, J., 2018. Appropriateness to set a group health-based guidance value for fumonisins and their modified forms. EFSA J. 16. https://doi.org/10.2903/j.efsa.2018.5172
Gelineau-van Waes, J., Rainey, M.A., Maddox, J.R., Voss, K.A., Sachs, A.J., Gardner, N.M., Wilberding, J.D., Riley, R.T., 2012. Increased sphingoid base-1-phosphates and failure of neural tube closure after exposure to fumonisin or FTY720. Birth Defects Res. Part A - Clin. Mol. Teratol. 94, 790–803. https://doi.org/10.1002/bdra.23074
Riley, R.T., Merrill, A.H., 2019. Ceramide synthase inhibition by fumonisins: A perfect storm of perturbed sphingolipid metabolism, signaling, and disease. J. Lipid Res. 60, 1183–1189. https://doi.org/10.1194/jlr.S093815
Sassa, T., Hirayama, T., Kihara, A., 2016. Enzyme activities of the ceramide synthases CERS2-6 are regulated by phosphorylation in the C-terminal region. J. Biol. Chem. 291, 7477–7487. https://doi.org/10.1074/jbc.M115.695858
Stiban, J., Tidhar, R., Futerman, A.H., 2010. Ceramide synthases: Roles in cell physiology and signaling. Adv. Exp. Med. Biol. 688, 60–71. https://doi.org/10.1007/978-1-4419-6741-1_4
Tidhar, R., Futerman, A.H., 2013. The complexity of sphingolipid biosynthesis in the endoplasmic reticulum. Biochim. Biophys. Acta - Mol. Cell Res. 1833, 2511–2518. https://doi.org/10.1016/j.bbamcr.2013.04.010